The Women TAF-FTC Benchmark Study
NCT05140954
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
54
Enrollment
OTHER
Sponsor class
Conditions
HIV Infections
Interventions
DRUG:
co-formulated 25mg TAF/ 200mg FTC
Sponsor
University of Washington
Collaborators
[object Object]
[object Object]
[object Object]